Companion Diagnostic Spoiler Alert: Start at the End Before You Begin

In this webinar, the attendees will gain insights into how they can evaluate potential companion diagnostic (CDx) partners not just for their development skills but for their proven ability to commercialize assays effectively. This knowledge is invaluable for pharmaceutical companies, biotech firms and all stakeholders in the healthcare continuum.

In the rapidly evolving landscape of precision medicine, the success of a therapy is often closely entwined with the effectiveness of its companion diagnostic (CDx). The journey to this success, as will be explained in this webinar and the whitepaper, “CDx Market Access: The Path to Precision Medicine Success,” begins with a counterintuitive yet strategic step — start with the end in mind.

During the webinar, the speaker will explore the balance between development, commercialization and the overarching implications for precision medicine therapies. The analysis offered intends to bridge the gap between development prowess and market strategy, underlining the necessity of a diagnostic partner who impresses not only in the lab but also excels in the market.

The diagnostic partner should have established channels for educating Physicians and driving awareness and adoption of new CDx tests, as well as integrated systems that facilitate ease of ordering and sample collection. This ensures that the right test is delivered to the right patient at the right time, a foundational principle of precision medicine.

Register for this webinar today to understand how potential companion diagnostic partners should be evaluated and how they can drive awareness and adoption of new CDx tests.

Speaker

Greg Baschkopf, Executive Director, CDx and IVD, Quest Diagnostics

Greg Baschkopf is a seasoned leader, currently serving as the Executive Director of Companion Diagnostics and IVD at Quest Diagnostics. Greg has amassed extensive experience and knowledge in molecular genetics, oncology and cell and gene therapy, making him a respected authority in the industry.

In his current role at Quest Diagnostics, Greg leads the CDx division, where he oversees the development and implementation of companion diagnostics solutions. His responsibilities include strategic planning, development oversight and partnership management. Under his leadership, the CDx team continues to innovate, bringing novel diagnostic assays to market and expanding the company’s footprint in precision medicine.

Message Presenter